PEGABTANIB
Drug #2345
Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration .
Primary Characteristics
Molecular Weight: 541.57 · Non-proprietary name: PEGABTANIB.
Pharmacokinetics
Elimination: it is metabolised via nucleases, plasma half-life is 10 days.
Advertisement
Indications
PEGABTANIB is primarily indicated in conditions like Macula degeneration.
Contraindications
None recorded.
Dosage
None recorded.
Drug Interactions
None recorded.
Side Effects
None recorded.
Warnings / Precautions
Intravitreous injections, including those with Macugen, have been associated with
endophthalmitis. Proper aseptic injection technique should always be utilized when
administering Macugen. In addition, patients should be monitored during the week following
the injection to permit early treatment.Increases in intraocular pressure have been seen within 30 minutes of injection with
Macugen. Therefore, intraocular pressure as well as the perfusion of the optic nerve head
should be monitored and managed appropriately .
Rare cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been
reported in the post-marketing experience following the Macugen intravitreal administration
procedure
Available Brands
None recorded.